conserving Loratadine and Pseudoephedrine enough

most leeway Loratadine and Pseudoephedrine ideal
 
Photo :Loratadine and Pseudoephedrine

quickens Loratadine and Pseudoephedrine Overview Side Effects Dosage Professional Interactions More Pregnancy Warnings User Reviews Drug Images Support Group Q & A Pricing & Coupons Pronunciation (lor AT a deen & soo doe e FED rin) Index Terms Loratadine/Pseudoephedrine P-Ephed Sul/Loratadine Pseudoephedrine and Loratadine Slideshow Flonase: Avoid These Top 9 Mistakes Dosage Forms Excipient information presented when available (limited, particularly for generics); consult specific product labeling. Tablet, extended release: Alavert Allergy and Sinus: Loratadine 5 mg and pseudoephedrine sulfate 120 mg Claritin-D 12 Hour Allergy & Congestion: Loratadine 5 mg and pseudoephedrine sulfate 120 mg [contains calcium 30 mg/tablet] Claritin-D 24 Hour Allergy & Congestion: Loratadine 10 mg and pseudoephedrine sulfate 240 mg [contains calcium 25 mg/tablet] Loratadine-D 12 Hour: Loratadine 5 mg and pseudoephedrine sulfate 120 mg Loratadine-D 24 Hour: Loratadine 10 mg and pseudoephedrine sulfate 240 mg Generic: Loratadine 5 mg and pseudoephedrine sulfate 120 mg; Loratadine 10 mg and pseudoephedrine sulfate 240 mg Brand Names: U.S. Alavert Allergy and Sinus [OTC] Claritin-D 12 Hour Allergy & Congestion [OTC] Claritin-D 24 Hour Allergy & Congestion [OTC] Loratadine-D 12 Hour [OTC] Loratadine-D 24 Hour [OTC] Pharmacologic Category Alpha/Beta Agonist Decongestant Histamine H 1 Antagonist Histamine H 1 Antagonist, Second Generation Piperidine Derivative Use: Labeled Indications Cold, allergy symptoms: Temporary relief of sinus and nasal congestion, runny nose, sneezing, itching of nose or throat and itchy, watery eyes due to common cold, hay fever (allergic rhinitis), or other upper respiratory allergies or sinusitis Contraindications Hypersensitivity to loratadine, pseudoephedrine, or any component of the formulation; during or within 14 days of MAOI therapy; severe hypertension or coronary heart disease Dosing: Adult Cold, allergy symptoms: Oral: Loratadine 5 mg/pseudoephedrine 120 mg per tablet: One tablet every 12 hours (maximum: 2 tablets/day) Loratadine 10 mg/pseudoephedrine 240 mg per tablet: One tablet daily (maximum: 1 tablet/day) Dosing: Geriatric Refer to adult dosing. Dosing: Pediatric Cold, allergy symptoms: Children 12 years and Adolescents: Oral: Refer to adult dosing. Dosing: Renal Impairment There are no dosage adjustments provided in the manufacturer s labeling; use with caution. Also see individual agents. Dosing: Hepatic Impairment There are no dosage adjustments provided in the manufacturer s labeling; use with caution. Also see individual agents. Administration Oral: Do not divide, chew, crush, or dissolve tablets. Storage Store between 20 C and 25 C (68 F and 77 F). Protect from light and store in a dry place. Drug Interactions AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. Monitor therapy Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. Monitor therapy Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Avoid combination Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Monitor therapy Alkalinizing Agents: May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). Monitor therapy Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation. Monitor therapy Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents. Monitor therapy Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine. Monitor therapy Amiodarone: May increase the serum concentration of Loratadine. Management: Due to reported QT interval prolongation and Torsades de Pointes with this combination, consider an alternative to loratadine when possible. Consider therapy modification Amodiaquine: CYP2C8 Inhibitors may increase the serum concentration of Amodiaquine. Avoid combination Amphetamines: May diminish the sedative effect of Antihistamines. Monitor therapy Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents. Monitor therapy AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). Avoid combination Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects. Consider therapy modification Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response. Consider therapy modification Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Monitor therapy Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Consider therapy modification Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Monitor therapy Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants. Consider therapy modification Cannabis: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy Carbonic Anhydrase Inhibitors: May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). Monitor therapy Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents. Monitor therapy Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Consider therapy modification Chloroprocaine: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Monitor therapy Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Monitor therapy Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. Avoid combination CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Monitor therapy Cocaine: May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Consider therapy modification Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Monitor therapy Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Monitor therapy Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended. Monitor therapy Dronabinol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use. Consider therapy modification Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. Avoid combination Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Exceptions: Ergoloid Mesylates; Nicergoline. Avoid combination Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Consider therapy modification Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Monitor therapy Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. Monitor therapy Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). Avoid combination Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Monitor therapy Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Consider therapy modification HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Consider therapy modification HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. Avoid combination Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents. Avoid combination Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. Monitor therapy Kava Kava: May enhance the adverse/toxic effect of CNS Depressants. Monitor therapy Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. Avoid combination Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. Monitor therapy Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established. Consider therapy modification MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Monitor therapy Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents. Monitor therapy Minocycline: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. Monitor therapy Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. Monitor therapy Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting). While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. Exceptions: Linezolid; Tedizolid. Avoid combination Nabilone: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. Monitor therapy OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. Monitor therapy Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics. Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Consider therapy modification Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Avoid combination Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents. Avoid combination Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Avoid combination OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Consider therapy modification Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Avoid combination Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination. Consider therapy modification P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). Monitor therapy P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). Monitor therapy Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Monitor therapy Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. Monitor therapy Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Avoid combination Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. Avoid combination Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Monitor therapy Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract. Consider therapy modification Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. Monitor therapy Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. Monitor therapy RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. Monitor therapy ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Monitor therapy Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Monitor therapy Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Monitor therapy Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. Consider therapy modification Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Monitor therapy Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists. Consider therapy modification Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated. Consider therapy modification Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Monitor therapy Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Consider therapy modification Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Consider therapy modification Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Avoid combination Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. Monitor therapy Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. Avoid combination Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Monitor therapy Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Avoid combination Urinary Acidifying Agents: May decrease the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). Monitor therapy Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Consider therapy modification Test Interactions See individual agents. Adverse Reactions See individual agents. Warnings/Precautions Disease-related concerns: Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease). Diabetes: Use with caution in patients with diabetes mellitus. Hepatic impairment: Use with caution in patients with hepatic impairment. Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma. Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction. Renal impairment: Use with caution in patients with renal impairment. Thyroid dysfunction: Use with caution in patients with thyroid dysfunction. Concurrent drug therapy issues: Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Other warnings/precautions: Self-medication (OTC use): When used for self medication (OTC), do not exceed the recommended doses; discontinue use and contact healthcare provider if symptoms do not improve within 7 days or are accompanied by fever; if nervousness, dizziness, or sleeplessness occur; or if an allergic reaction to the formulation occurs. Pregnancy Considerations See individual agents. Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Patient may experience dizziness, anxiety, insomnia, or fatigue (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients. Next Interactions Print this page Add to My Med List More about loratadine/pseudoephedrine Side Effects During Pregnancy Dosage Information Drug Images Drug Interactions Support Group Pricing & Coupons En Español 49 Reviews Add your own review/rating Drug class: upper respiratory combinations Consumer resources Loratadine and pseudoephedrine Professional resources Other brands: Alavert D-12 Hour Allergy and Sinus Related treatment guides Allergic Rhinitis Nasal Congestion} Drug Status OTC Availability Over the counter B Pregnancy Category No proven risk in humans N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA WADA Class Anti-Doping Classification Loratadine / pseudoephedrine Rating 49 User Reviews 6.8 /10 49 User Reviews 6.8 Rate it! Drug Class Upper respiratory combinations Related Drugs upper respiratory combinations Promethazine DM , Cheratussin AC , Mucinex DM Allergic Rhinitis prednisone , Zyrtec , promethazine , fluticasone nasal , loratadine , cetirizine , Flonase , triamcinolone , montelukast , Claritin , Singulair , More... Nasal Congestion sodium chloride nasal , epinephrine topical , pseudoephedrine , phenylephrine , Afrin , doxylamine , Sudafed Congestion , Claritin-D , loratadine / pseudoephedrine , Loratadine-D 24 Hour , Saline Nasal Mist , More... Loratadine / pseudoephedrine Images Loratadine / pseudoephedrine systemic 10 mg / 240 mg (RX724 ) View larger images} } declaring


state of no activity Loratadine and Pseudoephedrine along with your


EmoticonEmoticon